The UK and US have secured a important bilateral deal that will maintain no tariffs on British drug exports entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase funding on drugs through the NHS. This pledge ensures that duties on these key goods will stay at nothing for a duration of 36 months.
This agreement follows earlier warnings to dramatically increase tariffs on branded drug imports, with potential rates floated reaching double the cost.
"This agreement between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and establishes much-needed fairness to American-British medicine commerce," a statement said.
Trade Importance
Medicines constitute one of the the United Kingdom's biggest export categories to the US, which is clearly the primary market for leading British pharmaceutical firms.
Export figures reveal that in the year prior to last September, the UK exported pharmaceutical products totaling billions to the US. This amount made up nearly one-fifth of total UK exports in that span.
"This deal protects work, boosts funding and paves the way for the UK to emerge as a worldwide center for medical research," a minister commented.
Specific NHS Changes
The pact involves several notable pledges from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to double overall NHS spending on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must pay back to the NHS to control costs will be restricted at 15%. Previously, refunds were more than twenty percent.
Industry Background
The pact follows a protracted dispute between the pharmaceutical industry and the UK government over drug pricing and approval rates.
These tensions were exacerbated by claims that American customers were paying several times more for the same drugs than patients in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been directed toward projects in the United States.
The Science Minister acknowledged that the NHS needed to spend more on treatments, noting that its expenditure on drugs had shrunk as a percentage of its resources over the last ten years.
